Key Highlights

  • Cyclopharm (ASX:CYC) shares were up 4.17% at $0.375 during the 23 October 2026 session at 12:04 pm.
  • A 7 October 2026 announcement reported seven Chinese medical bodies naming Technegas the preferred ventilation agent.
  • The consensus followed July 2026 joint guidelines from US, European and ANZ societies.

Cyclopharm Ltd (ASX:CYC) shares were up 4.17% at $0.375 during the trading session on 23 October 2026, as at 12:04 pm, while the S&P/ASX 200 stood at 8,762.60, down 0.35% (30.60 points). Cyclopharm is an ASX-listed radiopharmaceutical company whose core product, Technegas, is used in functional lung ventilation imaging. In an announcement dated 7 October 2026, the company reported that seven Chinese medical bodies had jointly published an expert consensus naming Technegas as the preferred ventilation agent for lung imaging in pulmonary embolism.

Chinese Consensus Names Technegas as Preferred Agent

In its announcement dated 7 October 2026, Cyclopharm said the consensus was published in the October 2026 issue of the Chinese Journal of Tuberculosis and Respiratory Diseases, a peer-reviewed journal of the Chinese Medical Association. The first of its ten recommendations states that 99mTc-Technegas is recommended as the preferred radiopharmaceutical for ventilation imaging, with DTPA aerosol to be used only where Technegas is unavailable. The working group agreed the recommendation unanimously.

The consensus followed a survey of nuclear medicine departments at multiple Chinese hospitals, which found that practice varied in how lung scans were ordered and that interpretation depended heavily on specialist expertise. Its stated purpose is to standardise how the scan is performed and reported across China.

Seven Bodies and a Wider Set of Clinical Uses

The 7 October 2026 announcement listed the issuing organisations, led by the Chinese Thoracic Society of the Chinese Medical Association and including the Chinese Association of Chest Physicians, national pulmonary embolism and pulmonary hypertension groups, and nuclear medicine bodies.

The consensus also recognises lung V/Q imaging for screening, follow-up and assessing treatment response in pulmonary embolism and chronic thromboembolic pulmonary hypertension, including after balloon pulmonary angioplasty and pulmonary endarterectomy. It sets out a V/Q protocol for pregnant women with suspected pulmonary embolism, which the company linked to its Beyond PE strategy.

Earlier Guidelines and the Chinese Nuclear Medicine Market

Cyclopharm said the Chinese consensus follows joint guidelines released in July 2026 by SNMMI, EANM, ACNM and ANZSNM covering the United States, Europe, Australia and New Zealand, which described Technegas as generally preferred when available.

It also cited a 2024 national survey reporting 1,237 nuclear medicine departments in China, of which 787 offer SPECT imaging, with more than 2.7 million SPECT scans in 2023. Under the Medical Isotope Development Plan (2021 to 2035), China is expected to roughly double the scale of nuclear medicine by 2035.

About the Company and Business Overview

Cyclopharm Ltd (ASX:CYC) is a radiopharmaceutical company serving the global medical community, with an office in Kingsgrove, New South Wales. Its core product, Technegas, is an ultra-fine dispersion of radioactively labelled carbon produced from technetium-99m in a carbon crucible heated to around 2,700 degrees Celsius. The patient inhales the gas-like substance, and images are captured under a gamma or SPECT camera to evaluate functional lung ventilation.

Technegas has historically been used to diagnose pulmonary embolism and is being investigated in other conditions, including COPD, asthma and pulmonary hypertension. In the United States it is indicated for visualising pulmonary ventilation and evaluating pulmonary embolism, when paired with perfusion imaging, in adults and paediatric patients aged six and over. The company states that its footprint extends to most provinces across China. Its Beyond PE strategy extends the use of lung V/Q imaging beyond initial diagnosis.

Related Sector Context

Nuclear medicine uses radioactive tracers with imaging equipment to assess organ function and disease. The company describes demand for lung scans as beginning with the referring physician, with adoption decisions made by hospital committees drawn from several disciplines.

The S&P/ASX 200 stood at 8,762.60 at 12:04 pm on 23 October 2026, down 0.35%, while Cyclopharm shares were higher during the same session.

Risks to Weigh In

A consensus statement is a clinical recommendation rather than a purchasing commitment, and the announcement does not quantify any sales effect in China. Hospital adoption depends on committee decisions, funding and regulatory arrangements in each market.

The company's results are linked to a single core product, and developments in other disease states remain at the investigation stage.

Catalysts on Watch

The announcement did not set specific dates for upcoming events. It did refer to the company's Beyond PE strategy, which covers uses of V/Q imaging beyond initial diagnosis, and to the expansion of nuclear medicine in China under the 2021 to 2035 isotope development plan.

The company also pointed to ongoing investigation of Technegas in other disease states, including COPD, asthma and pulmonary hypertension, as well as interventional applications such as lobectomies in lung cancer.

Where Things Stand

Cyclopharm shares traded 4.17% higher at $0.375 during the 23 October 2026 session. The company's latest update, dated 7 October 2026, reported a unanimous Chinese expert consensus naming Technegas as the preferred ventilation agent in pulmonary embolism imaging, following guidelines released in July 2026.